 ROCKVILLE, Md. , Oct. 27, 2022 PRNewswire -- REGENXBIO Inc. Nasdaq: RGNX today announced that it will present data from the ALTITUDE clinical trial evaluating RGX-314 using suprachoroidal delivery for the treatment of patients with diabetic retinopathy at the Retina Society 55th Annual Scientific Meeting taking place in Pasadena, CA, from November 2-5, 2022. 